Antibody discovery platform Immunocan closes RMB250 million Series A

Every Wednesday and Friday, TechNode’s Briefing newsletter delivers a roundup of the most important news in China tech, straight to your inbox. Your support helps TechNode continue to provide credible, on-the-ground journalism and industry insights about the Chinese tech industry. Shanghai-based Immunocan has closed a RMB250 million Series A round led by Vivo Capital, with participation from Gold Mine Multi Family Office and follow-on backing from existing investors including Kingray Capital and TigerYeah Capital. The company said the funds will be used to advance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, build an AI-driven antibody drug screening platform, and expand its team. Founded in 2020, Immunocan develops antibody discovery platforms based on gene-editing technologies. The company said it has built a multi-species platform portfolio spanning mouse, alpaca, and rabbit models, while also advancing its MabAI platform for AI-based antibody generation and characterization. Immunocan added that it is already working with multiple domestic and international pharmaceutical companies, including several top global drugmakers. [TechNode reporting]

Read the full article at the source →